Stress-reducing Intervention in Urothelial Carcinoma
- Disease/Condition
- Bladder Cancer
- Drug/Device/Intervention
- HRV biofeedback
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- Comenius University
- Location
- Bratislava, Slovakia
- Phase
- N/A
- Start date
- Feb 15, 2024
- End date
- Feb 15, 2029
- Enrollment
- 50 participants
Primary Objective: Inflammation,Primary Objective: Heart Rate Variability (HRV),Primary Objective: Quality of Life (QoL),Primary Objective: Working memory,Primary objective: Executive function,Primary objective: Salivary Cortisol Slopes,Primary objective: Sleep Quality
The aim of this interventional study is to test the heart-rate variability biofeedback
 intervention (HRV BI) in patients with muscle-infiltrating bladder carcinoma (MIBC) treated
 with chemotherapy based on cisplatin in neoadjuvant setting followed by local therapy
 (standard of care, SOC) compared to SOC alone.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06269536
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06269536 through Pure Global AI's free database. This phase not specified trial is sponsored by Comenius University and is currently Recruiting. The study focuses on Bladder Cancer. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.